Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword

Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Mengwan, Shi, Ying, Zhu, Luyi, Chen, Luoyi, Zhao, Xinchen, Xu, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409650/
https://www.ncbi.nlm.nih.gov/pubmed/36013403
http://dx.doi.org/10.3390/life12081225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409650/
https://www.ncbi.nlm.nih.gov/pubmed/36013403
http://dx.doi.org/10.3390/life12081225

Ejemplares similares